Company profile
Koutif Therapeutics company profile
Koutif Therapeutics is advancing discoveries from researchers at the University of Pittsburgh. Their academic founders are developing an inhibitor of E3 ligase Fbxo3, which is implicated in the pathogenesis of inflammatory conditions such as neuropathic pain, bronchiolitis obliterans syndrome, irritable bowel disease, chronic obstructive pulmonary disease, rheumatoid arthritis, and acute lung injury.
Business identity
- Contact email
- [email protected]
- Operating status
- Active
- Company type
- For Profit
- Employee range
- 11-50 employees
- Revenue range
- $0+
- Founded
- 2017-01-01, Year
Headquarters
- Headquarters
- The Bronx, New York, United States
- Postal code
- OH 44122
- Country code
- US
- Continent
- North America